Increasing Autoimmune Disease Prevalence Drives Rheumatology Therapeutics Market Growth: Pivotal Factor Influencing Rheumatology Therapeutics Market Growth in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Rheumatology Therapeutics Market Size Growth Forecast: What to Expect by 2025?
The market for rheumatology therapeutics has seen robust growth in the recent past. The market size is expected to expand from $42.4 billion in 2024 to $44.61 billion in 2025, marking a compound annual growth rate (CAGR) of 5.2%. This surge during the historical period is influenced by factors such as an increase in rheumatologic disorders, a globally aging population, greater knowledge about available treatments, improvements in biological therapies, and the broadening of healthcare access in emerging markets.

How Will the Rheumatology Therapeutics Market Size Evolve and Grow by 2029?
The market for rheumatology therapeutics is anticipated to experience a consistent growth in the coming years, expanding to $53.88 billion by 2029 with a 4.8% compound annual growth rate (CAGR). This growth during the prediction period can be linked to the inclination towards personalized medicine strategies, the increasing acceptance of biosimilars in rheumatology, enhanced investment in R&D, incorporation of digital health technologies, and approval of new therapies by regulatory authorities. The forthcoming period will witness trends such as the expansion of telemedicine and remote monitoring solutions, development of targeted treatments for specific rheumatological conditions, focus on patient-centric care models, proliferation of biologic treatments beyond monoclonal antibodies, and the shift to value-based pricing models.

View the full report here:
https://www.thebusinessresearchcompany.com/report/rheumatology-therapeutics-global-market-report

What Drivers Are Propelling the Growth of Rheumatology Therapeutics Market Forward?
The increasing occurrence of autoimmune diseases is anticipated to accelerate the expansion of the rheumatology therapeutics market. Autoimmune diseases are conditions in which the immune system erroneously attacks and harms the body's tissues. The growing occurrence of these diseases can be attributed to genetic, environmental, and lifestyle factors, as well as enhanced awareness and diagnostic abilities. Therapies in rheumatology are crucial in treating autoimmune diseases as they control inflammation, relieve symptoms, and prevent damage to joints and tissues due to the immune system's attack on the body. For example, the Australian Institute of Health and Welfare reported in June 2024 that roughly 514,000 individuals in Australia, or 2.0% of the population, were projected to be suffering from rheumatoid arthritis in 2022. Rheumatoid arthritis was responsible for 2.0% of the overall disease load and 16% of the load for all musculoskeletal conditions in 2023. Hence, the increasing occurrence of autoimmune diseases is fueling the expansion of the rheumatology therapeutics market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17246&type=smp

Which Emerging Trends Are Transforming the Rheumatology Therapeutics Market in 2025?
Leading enterprises in the rheumatology therapeutics industry are introducing groundbreaking solutions such as intravenous (IV) formulations to improve the effectiveness of treatments and the convenience for patients. An intravenous (IV) formulation involves the direct administration of medication or substance into a vein via a needle or catheter. For example, in October 2023, Switzerland-based Novartis AG, a leading pharmaceutical firm, revealed that its intravenous (IV) formulation, Cosentyx, had received approval from the US Food and Drug Administration (FDA). This particular version of Cosentyx is exclusively approved to treat adults suffering from psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA). In terms of mechanism, it specifically focuses on and inhibits interleukin-17A (IL-17A) and is the sole non-tumor necrosis factor alpha (TNF-a) IV treatment available for these ailments.

What Are the Key Segments in the Rheumatology Therapeutics Market?
The rheumatology therapeutics market covered in this report is segmented -

1) By Drug Class: Disease Modifying Anti-Rheumatic Drugs, Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Other Drugs Classes
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
3) By Disease Indication: Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, Ankylosing Spondylitis, Other Disease Indications

Subsegments:
1) By Disease Modifying Anti-Rheumatic Drugs (DMARDs): Conventional Synthetic DMARDs, Biologic DMARDs, Targeted Synthetic DMARDs
2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): COX-2 Inhibitors, Traditional NSAIDs
3) By Corticosteroids: Oral Corticosteroids, Injectable Corticosteroids, Topical Corticosteroids
4) By Uric Acid Drugs: Uric Acid Lowering Agents, Uricosuric Agents, Pegloticase
5) By Other Drug Classes: Immunosuppressants, Biologic Therapies, Analgesics

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=17246&type=smp

Who Are the Key Players Shaping the Rheumatology Therapeutics Market's Competitive Landscape?
Major companies operating in the rheumatology therapeutics market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Janssen Biotech, Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals, UCB S.A., Galapagos NV (GLPG), Genentech Inc.

What Geographic Markets Are Powering Growth in the Rheumatology Therapeutics Market?
North America was the largest region in the rheumatology therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rheumatology therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17246

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.